Bio-Techne Corp (TECH) : Fridays money flow points at investors jumping to buy the stock on the weakness of price. $4.96 million worth of transactions were on upticks, whereas, the downticks accounted for $3.14 million worth of transactions. The net money flow was a positive $1.82 million and the uptick to downtick ratio was 1.58. The net money flow into the stock was $1.97 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $1.97 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. Bio-Techne Corp (TECH) was trading at $110.75, down $0.14 during day. The stock slid -0.13% over the previous days close. For the week, the stock recorded -0.15% over the previous weeks close.
Bio-Techne Corp (TECH) : The highest level Bio-Techne Corp (TECH) is projected to reach is $118 for the short term and the lowest estimate is at $105. The consolidated price target from 4 rating analysts who initiate coverage on the stock is $113.5 and the possibility the share price can swing is $5.8.
Bio-Techne Corp (NASDAQ:TECH): On Fridays trading session , Opening price of the stock was $111.21 with an intraday high of $111.32. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $110.54. However, the stock managed to close at $110.75, a loss of 0.13% for the day. On the previous day, the stock had closed at $110.89. The total traded volume of the day was 129,838 shares.
In a related news, The Securities and Exchange Commission has divulged that Lucas Roger C, director of Bio-Techne Corp, had unloaded 100 shares at an average price of $92.4 in a transaction dated on April 20, 2016. The total value of the transaction was worth $9,240.
Bio-Techne Corporation (Bio-Techne), formerly Techne Corporation, develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products around the world. The Company has three business segments: the Biotechnology, Clinical Controls and Protein Platforms divisions. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products around the world. The Clinical Controls segment develops and manufactures controls and calibrators for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. Bio-Techne is engaged in providing specialized proteins, including cytokines and growth factors, antibodies, related immunoassays, biologically active small molecules, and other reagents to the research, diagnostics and clinical controls markets.